Scholar Rock Holding Corp at Goldman Sachs Healthcare Conference Transcript
We can get started. We have David Hallal from Scholar Rock here with us. Thank you so much for joining us.
Maybe to start, if you could provide just an overview of your company for those who may not be familiar, including the updates that we'll see within the next year.
Great. Thanks, Tommy. It's great to be here once again at the 47th Goldman Sachs Healthcare Conference. David Hallal, Chairman and CEO of Scholar Rock, which is a Cambridge-based biotech company that has been focused on myostatin biology. And we're very proud that we are the world leaders in myostatin biology.
This is obviously a target that was identified in 1997. The first anti-myostatin inhibitor went into the clinic in 2004, 2005. And really, over the period of these last 20-some years, there have been multiple milestone inhibitors that have failed in clinical development. We stand alone with our unique technology platform and approach to myostatin biology as the first and only
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
